| Systematic (IUPAC) name | |
|---|---|
| N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| ATC code | ? |
| PubChem | CID 9934746 |
| ChemSpider | 8110374 |
| Synonyms | 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one |
| Chemical data | |
| Formula | C26H31N5O4 |
| Mol. mass | 477.554 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
RPL-554 (LS-193,855) is a drug which acts as a long-acting inhibitor of the phosphodiesterase enzymes PDE-3 and PDE-4, producing both bronchodilator and antiinflammatory effects.[1] It is being developed by Verona Pharma as a potential treatment for asthma and hayfever, and is currently in clinical trials.[2][3]
|
||||||||||||||||||||||||||||||||